Interleukin 1β Mediates Intestinal Inflammation in Mice and Patients With Interleukin 10 Receptor Deficiency

2016/09/30 by Dror S. Shouval, Amlan Biswas, Yu Hui Kang +27 · 28 citations
Biochemistry, Genetics and Molecular Biology · Immunology and Microbiology · #Inflammasome and immune disorders #IL-33, ST2, and ILC Pathways #Immune Cell Function and Interaction

paper · doi:10.1053/j.gastro.2016.08.055

Citations

• Loss of Interleukin-10 Signaling and Infantile Inflammatory Bowel Disease: Implications for Diagnosis and Therapy

Cited by

• The clinical, molecular, and therapeutic features of patients with IL10/IL10R deficiency: a systematic review
• Pyroptosis in neutrophils: Multimodal integration of inflammasome and regulated cell death signaling pathways
• Toll-like Receptors and the Control of Immunity
• Myeloid-derived miR-223 regulates intestinal inflammation via repression of the NLRP3 inflammasome. [europepmc]
• Inflammasomes and Cancer: The Dynamic Role of the Inflammasome in Tumor Development. [europepmc]
• The Antioxidant Procyanidin Reduces Reactive Oxygen Species Signaling in Macrophages and Ameliorates Experimental Colitis in Mice. [europepmc]
• Loss-of-function CARD8 mutation causes NLRP3 inflammasome activation and Crohn's disease. [europepmc]
• Antibiotics induce sustained dysregulation of intestinal T cell immunity by perturbing macrophage homeostasis. [europepmc]
• The Role of NLRP3 and IL-1β in the Pathogenesis of Inflammatory Bowel Disease. [europepmc]
• VSIG4 mediates transcriptional inhibition of Nlrp3 and Il-1 β in macrophages. [europepmc]
• NLRP3 Inflammasome and Inflammatory Bowel Disease. [europepmc]
• Anti-TNF therapy in IBD exerts its therapeutic effect through macrophage IL-10 signalling. [europepmc]
• Very Early Onset Inflammatory Bowel Disease: A Clinical Approach With a Focus on the Role of Genetics and Underlying Immune Deficiencies. [europepmc]
• Serum Amyloid A Proteins Induce Pathogenic Th17 Cells and Promote Inflammatory Disease. [europepmc]
• Human β-Defensin 2 Mediated Immune Modulation as Treatment for Experimental Colitis. [europepmc]
• Pathway paradigms revealed from the genetics of inflammatory bowel disease. [europepmc]
• Toll-like Receptors and the Control of Immunity. [europepmc]
• Gut-resident CX3CR1 hi macrophages induce tertiary lymphoid structures and IgA response in situ. [europepmc]
• IL-10 and IL-22 in Mucosal Immunity: Driving Protection and Pathology. [europepmc]
• Deconvolution of monocyte responses in inflammatory bowel disease reveals an IL-1 cytokine network that regulates IL-23 in genetic and acquired IL-10 resistance. [europepmc]
• Monogenic autoinflammatory disorders: Conceptual overview, phenotype, and clinical approach. [europepmc]
• Clinical Genomics for the Diagnosis of Monogenic Forms of Inflammatory Bowel Disease: A Position Paper From the Paediatric IBD Porto Group of European Society of Paediatric Gastroenterology, Hepatology and Nutrition. [europepmc]
• Intestinal Stem Cells and Immune Cell Relationships: Potential Therapeutic Targets for Inflammatory Bowel Diseases. [europepmc]
• Tiliroside Ameliorates Ulcerative Colitis by Restoring the M1/M2 Macrophage Balance via the HIF-1α/glycolysis Pathway. [europepmc]
• IL-1-driven stromal-neutrophil interactions define a subset of patients with inflammatory bowel disease that does not respond to therapies. [europepmc]
• An Integrated Taxonomy for Monogenic Inflammatory Bowel Disease. [europepmc]
• Pattern Recognition Receptor Signaling and Cytokine Networks in Microbial Defenses and Regulation of Intestinal Barriers: Implications for Inflammatory Bowel Disease. [europepmc]
• Immune regulation by fungal strain diversity in inflammatory bowel disease. [europepmc]